Luteolin Attenuates Diabetic Myocardial Hypertrophy by Inhibiting Proteasome Activity
Conclusion: This study indicates that luteolin protected against DCM in mice, including T1DM and T2DM, by upregulating phosphorylated protein AMPK and AKT/GSK-3 pathways while decreasing the proteasome activity. These findings suggest that luteolin may be a potential therapeutic agent for DCM.Pharmacology
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiomyopathy | Cholesterol | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Flavonoids | Heart | Insulin | Obesity | Perinatology & Neonatology | Study